[Federal Register Volume 83, Number 88 (Monday, May 7, 2018)]
[Notices]
[Pages 20083-20084]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-09656]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S.

[[Page 20084]]


FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; 
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may 
be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing. A description of the 
technology follows.

Inner Curvature Charge Concentration Device For Tissue Laceration

    Description of Technology: Left ventricular outflow tract 
obstruction is a life-threatening complication of transcatheter mitral 
valve replacement caused by septal displacement of the anterior mitral 
leaflet (AML). The AML is a mobile structure that physically separates 
inflow and outflow zones of the left ventricle. Preserving the AML 
during surgical mitral valve replacement can cause left ventricular 
outflow tract obstruction, either when the prosthesis struts protrude 
into the left ventricular outflow tract or when along redundant 
anterior leaflet prolapses into the left ventrical outflow tract. The 
invention relates to devices having monopolar or bipolar tissue 
lacerators for efficiently and safely cutting AMLs percutaneously by 
vaporizing target tissue with electrical energy. Exemplary devices 
include a wire partially covered by electrical insulation, where the 
wire is kinked and where the wire is exposed through the insulation at 
one or more exposed regions along or near the inner curvature of the 
kink. The wire is configured to conduct electrical energy through the 
exposed region(s) and through a tissue target positioned adjacent the 
inner curvature to lacerate the tissue target via the electrical 
energy. The tissue target can be a native or prosthetic heart valve 
leaflet in a patient's heart. An optional feature of the device also 
includes an irrigation catheter to displace blood from the electrode, 
concentrating current at the tissue and reducing char and coagulum 
formation.

Potential Commercial Applications:

 Prevention of iatrogenic left ventricular outflow tract 
obstruction following transcatheter mitral valve replacement
 Bioprosthetic aortic scallop intentional laceration

Development Stage:

 In vivo data available
    Inventors: Robert Lederman, Jaffar Khan, Toby Rogers (all of 
NHLBI).
    Intellectual Property: HHS Reference No. E-064-2018/0-US-01; U.S. 
Provisional Patent Application 62/633,791 filed February 22, 2018.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Environmental Health Sciences seeks statements of capability or 
interest from parties interested in collaborative research to further 
develop and evaluate, please contact Peg Koelble, Technology 
Development Specialist, Office of Technology Transfer, National Heart, 
Lung, and Blood Institute, Phone: 301.594.4095; [email protected].

    Dated: April 26, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-09656 Filed 5-4-18; 8:45 am]
 BILLING CODE 4140-01-P